Guangming Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Guangming Li has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Lishan Su
Institute of Human Virology University of Maryland School of Medicine Baltimore Maryland USA
3 shared publications Yaoxian Lou
Institute of Human Virology University of Maryland School of Medicine Baltimore Maryland USA
3 shared publicationsJianping Ma
Lineberger Comprehensive Cancer Center, Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
2 shared publications- Ourania Tsahouridis
Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC
2 shared publications - Poonam Mathur
Institute of Human Virology University of Maryland School of Medicine Baltimore Maryland USA
2 shared publications - Andrew Kennedy
Department of Cell Biology and Physiology, The University of North Carolina, Chapel Hill, NC
1 shared publication
Latest Publications
- Open Access
- 2 November 2026
- Published by Wiley in HIV Medicine
In vitro NAD + supplementation increases CD4 + and CD8 + T cell function in people with HIV
Objectives: HIV perturbs T cell homeostasis and disrupts immune function, increasing the risk of age‐associated comorbidities. Ageing people with HIV (PWH) have exacerbated expression of CD38 on T cells, which depletes intracellular nicotinamide adenine dinucleotide (NAD+). We investigated whether boosting intracellular NAD+ could restore T cell homeostasis and function. Methods: We collected blood samples from virally suppressed PWH to determine the effects of in vitro NAD+ on CD38 expression and T cell function in response to anti‐CD3/CD28 antibodies stimulation in PBMCs culture supplemented with IL‐2 and IL‐7. Results: We observed that NAD+ supplementation not only reduced expression of CD38 but also improved T cell function with an alleviated exhaustion phenotype in response to anti‐CD3/CD28 antibodies stimulation. Conclusions: If confirmed in clinical trials, NAD+ supplementation has the potential to restore T cell homeostasis and immune function in PWH and ameliorate age‐associated comorbidities.
- 2 November 2026
- Published by Wiley in HIV Medicine
Open AccessIn vitro NAD + supplementation increases CD4 + and CD8 + T cell function in people with HIV
Objectives: HIV perturbs T cell homeostasis and disrupts immune function, increasing the risk of age‐associated comorbidities. Ageing people with HIV (PWH) have exacerbated expression of CD38 on T cells, which depletes intracellular nicotinamide adenine dinucleotide (NAD+). We investigated whether boosting intracellular NAD+ could restore T cell homeostasis and function. Methods: We collected blood samples from virally suppressed PWH to determine the effects of in vitro NAD+ on CD38 expression and T cell function in response to anti‐CD3/CD28 antibodies stimulation in PBMCs culture supplemented with IL‐2 and IL‐7. Results: We observed that NAD+ supplementation not only reduced expression of CD38 but also improved T cell function with an alleviated exhaustion phenotype in response to anti‐CD3/CD28 antibodies stimulation. Conclusions: If confirmed in clinical trials, NAD+ supplementation has the potential to restore T cell homeostasis and immune function in PWH and ameliorate age‐associated comorbidities.
- 20 August 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (8) , 982-994
High-avidity cathepsin-G–specific CAR T cells for the treatment of acute myeloid leukemia
Chimeric antigen receptor (CAR) T cells specific for myeloid-associated antigens expressed on the cell surface of acute myeloid leukemia (AML) can cause depletion of normal myeloid progenitor cells. We developed a CAR specific for an HLA-A∗02:01-restricted peptide of the myeloid-restricted cathepsin-G (CG) protein. CG-specific CAR T cells (CG1.CAR) were further engineered to increase their functional avidity. Specifically, we developed CG1.CAR T cells coexpressing the lymphocyte-specific protein tyrosine kinase (LCK) and duplicated CD3ζ chain, which allows the functional recognition of the CG1 peptide as low as 0.025μM. Optimized CG1.CAR T cells displayed antileukemia effects in vitro and in vivo in patient-derived AML xenotransplant mouse models and did not cause hematopoietic toxicity in colony assays and humanized mice. Mechanistically, LCK overexpression in CG1.CAR T cells caused transcriptional modifications characterized by the overexpression of mitochondrial-encoded electron transport chain components that were correlated with increased mitochondrial mass and improved respiratory capacity. Based on these data, CG1.CAR T cells hold clinical potential for the treatment of AML.
- 20 August 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (8) , 982-994
High-avidity cathepsin-G–specific CAR T cells for the treatment of acute myeloid leukemia
Chimeric antigen receptor (CAR) T cells specific for myeloid-associated antigens expressed on the cell surface of acute myeloid leukemia (AML) can cause depletion of normal myeloid progenitor cells. We developed a CAR specific for an HLA-A∗02:01-restricted peptide of the myeloid-restricted cathepsin-G (CG) protein. CG-specific CAR T cells (CG1.CAR) were further engineered to increase their functional avidity. Specifically, we developed CG1.CAR T cells coexpressing the lymphocyte-specific protein tyrosine kinase (LCK) and duplicated CD3ζ chain, which allows the functional recognition of the CG1 peptide as low as 0.025μM. Optimized CG1.CAR T cells displayed antileukemia effects in vitro and in vivo in patient-derived AML xenotransplant mouse models and did not cause hematopoietic toxicity in colony assays and humanized mice. Mechanistically, LCK overexpression in CG1.CAR T cells caused transcriptional modifications characterized by the overexpression of mitochondrial-encoded electron transport chain components that were correlated with increased mitochondrial mass and improved respiratory capacity. Based on these data, CG1.CAR T cells hold clinical potential for the treatment of AML.
- Open Access
- 19 June 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (8) , 113269
Antibody glyco-optimization and site-specific conjugation enhance the immune-stimulating activity of antibody-TLR ligand conjugates
- 19 June 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (8) , 113269
Open AccessAntibody glyco-optimization and site-specific conjugation enhance the immune-stimulating activity of antibody-TLR ligand conjugates
- 5 November 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (823) , eadr3930
Depletion of plasmacytoid dendritic cells rescues HIV-reactive stem-like CD8 + T cells during chronic HIV-1 infection
Plasmacytoid dendritic cells (pDCs) rapidly produce type I interferon (IFN-I) in response to acute virus infections. During chronic HIV-1 infection, persistent activation of pDCs contributes to inflammatory diseases. Combination antiretroviral therapy (cART) effectively suppresses HIV-1 replication and prolongs the life span of people living with HIV-1 (PLWH). The persistence of viral reservoir cells under cART, however, is associated with suboptimal immune reconstitution, impaired anti-HIV immunity, and non–AIDS-defining inflammatory diseases through unclear mechanisms. We report here that pDC depletion in HIV-infected humanized mice with suppressive cART alleviated HIV-associated inflammation, reversed T cell immune exhaustion, enhanced HIV-specific CD8 + T cell responses, and reduced HIV-1 reservoirs in lymphoid and nonlymphoid tissues through CD8 + T cell–dependent mechanisms. Specifically, pDC depletion in the mice led to an increase in TCF-1 + PD-1 + Tim-3 − stem-like memory CD8 + T cells in HIV-infected lymphoid tissues, which correlated with a reduction in the HIV-1 reservoir. We further showed that pDCs suppressed the polyfunctional activity of anti-HIV stem-like memory CD8 + T cells isolated from PLWH in vitro. As in the HIV-infected humanized mice, pDC depletion or IFN-I blockade functionally rescued the stem-like memory CD8 + T cells, enhancing their anti-HIV responses. Combination therapy with PD-1 blockade further improved stem-like memory T cell function both in vitro and in HIV-infected humanized mice. Our findings indicate that HIV-induced inflammatory pDCs impair anti-HIV stem-like memory CD8 + T cell responses and suggest that the combination of pDC depletion with PD-1 immune checkpoint blockade represents a candidate therapeutic approach to treating HIV-1 infection and its associated inflammatory diseases.
- 5 November 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (823) , eadr3930
Depletion of plasmacytoid dendritic cells rescues HIV-reactive stem-like CD8 + T cells during chronic HIV-1 infection
Plasmacytoid dendritic cells (pDCs) rapidly produce type I interferon (IFN-I) in response to acute virus infections. During chronic HIV-1 infection, persistent activation of pDCs contributes to inflammatory diseases. Combination antiretroviral therapy (cART) effectively suppresses HIV-1 replication and prolongs the life span of people living with HIV-1 (PLWH). The persistence of viral reservoir cells under cART, however, is associated with suboptimal immune reconstitution, impaired anti-HIV immunity, and non–AIDS-defining inflammatory diseases through unclear mechanisms. We report here that pDC depletion in HIV-infected humanized mice with suppressive cART alleviated HIV-associated inflammation, reversed T cell immune exhaustion, enhanced HIV-specific CD8 + T cell responses, and reduced HIV-1 reservoirs in lymphoid and nonlymphoid tissues through CD8 + T cell–dependent mechanisms. Specifically, pDC depletion in the mice led to an increase in TCF-1 + PD-1 + Tim-3 − stem-like memory CD8 + T cells in HIV-infected lymphoid tissues, which correlated with a reduction in the HIV-1 reservoir. We further showed that pDCs suppressed the polyfunctional activity of anti-HIV stem-like memory CD8 + T cells isolated from PLWH in vitro. As in the HIV-infected humanized mice, pDC depletion or IFN-I blockade functionally rescued the stem-like memory CD8 + T cells, enhancing their anti-HIV responses. Combination therapy with PD-1 blockade further improved stem-like memory T cell function both in vitro and in HIV-infected humanized mice. Our findings indicate that HIV-induced inflammatory pDCs impair anti-HIV stem-like memory CD8 + T cell responses and suggest that the combination of pDC depletion with PD-1 immune checkpoint blockade represents a candidate therapeutic approach to treating HIV-1 infection and its associated inflammatory diseases.
- Open Access
- 8 August 2025
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 21 (8) , e1012826
CD24-Fc resolves inflammation and enhances anti-HIV CD8 T cells with polyfunctionality during HIV-1 infection under cART
The persistence of HIV-1 reservoirs during combination anti-retroviral therapy (cART) is associated with chronic inflammation and systemic immune activation in people infected with HIV-1 (PWH), leading to a suboptimal immune reconstitution as well as an increased risk of non-AIDS events. In this study, we assessed the effect of CD24-Fc, a fusion protein with anti-inflammatory properties that interacts with danger-associated molecular patterns (DAMPs) and siglec-10, in humanized mice with chronic HIV-1 infection under suppressive cART in vivo and in peripheral blood mononuclear cells (PBMCs) from PWH in vitro. We report that CD24-Fc treatment significantly reduced inflammation and immune hyperactivation in humanized mice with HIV-1 infection and cART. CD24-Fc treatment improved recovery of CD4 T cells, reduced immune hyper-activation, increased functional central memory T cells. Notably, CD24-Fc treatment increased CXCR5 + CD8 central memory T cells (TCM) with increased HIV-specific polyfunctionality in humanized mice and in PBMC from PWH. This enhanced anti-HIV T cell activity was associated with improved control of HIV-1 viral rebound and reduced HIV-1 pathogenesis upon cART cessation. Our findings indicate that CD24-Fc may provide a promising new therapeutic for treating chronic inflammation and associated diseases in PWH.
- 8 August 2025
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 21 (8) , e1012826
Open AccessCD24-Fc resolves inflammation and enhances anti-HIV CD8 T cells with polyfunctionality during HIV-1 infection under cART
The persistence of HIV-1 reservoirs during combination anti-retroviral therapy (cART) is associated with chronic inflammation and systemic immune activation in people infected with HIV-1 (PWH), leading to a suboptimal immune reconstitution as well as an increased risk of non-AIDS events. In this study, we assessed the effect of CD24-Fc, a fusion protein with anti-inflammatory properties that interacts with danger-associated molecular patterns (DAMPs) and siglec-10, in humanized mice with chronic HIV-1 infection under suppressive cART in vivo and in peripheral blood mononuclear cells (PBMCs) from PWH in vitro. We report that CD24-Fc treatment significantly reduced inflammation and immune hyperactivation in humanized mice with HIV-1 infection and cART. CD24-Fc treatment improved recovery of CD4 T cells, reduced immune hyper-activation, increased functional central memory T cells. Notably, CD24-Fc treatment increased CXCR5 + CD8 central memory T cells (TCM) with increased HIV-specific polyfunctionality in humanized mice and in PBMC from PWH. This enhanced anti-HIV T cell activity was associated with improved control of HIV-1 viral rebound and reduced HIV-1 pathogenesis upon cART cessation. Our findings indicate that CD24-Fc may provide a promising new therapeutic for treating chronic inflammation and associated diseases in PWH.